Advertisement

Molecular and Cellular Biochemistry

, Volume 409, Issue 1–2, pp 163–176 | Cite as

Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells

  • Oana TudoranEmail author
  • Olga Soritau
  • Loredana Balacescu
  • Simona Visan
  • Otilia Barbos
  • Roxana Cojocneanu-Petric
  • Ovidiu Balacescu
  • Ioana Berindan-Neagoe
Article

Abstract

Different molecular changes have been previously associated with therapeutic response and recurrent disease, however, the detailed mechanism of action in triple-negative breast cancer subtype remains elusive. In this study, we investigated the cellular and molecular signaling of two claudin-low triple-negative breast cancer cells to doxorubicin and docetaxel treatment. Whole human transcriptomic evaluation was used to identify the subsequent changes in gene expression, while biological effects were measured by means of proliferation and anchorage-independent growth assays. Microarray analysis revealed changes in stem cell-related signaling pathways, suggesting that doxorubicin treatment affects the balance between self-renewal and differentiation. While the treatment reduced the proliferation, aggregation and mammosphere forming ability of stem-like cells derived from Hs578T cell line, stem-like cells derived from MDA-MB-231 cells were not significantly affected. Our results suggest that claudin-low triple-negative breast cancer cells might predominantly alter stem cell-related signaling pathways to promote stem-like cells activity as an innate resistance mechanism to doxorubicin treatment.

Keywords

Triple negative phenotype Breast cancer Cancer stem-like cells Chemotherapy Microarray analysis 

Notes

Acknowledgments

This work was financed by the POSCCE 709/2010 grant with the title: “Clinical and economical impact of proteome and transcriptome molecular profiling in neoadjuvant therapy of triple negative breast cancer (BREASTIMPACT)”, and published under the frame of European Social Fund, Human Resources Development Operational Programme 2007–2013, Project No. POSDRU/159/1.5/S/138776.

Supplementary material

11010_2015_2522_MOESM1_ESM.pdf (124 kb)
Online resource 1 Microarray top 100 gene expression data of doxorubicin treatment of Hs578T cells (pdf 124 kb)
11010_2015_2522_MOESM2_ESM.pdf (117 kb)
Online resource 2 Microarray gene expression data of docetaxel treatment of Hs578T cells (pdf 116 kb)
11010_2015_2522_MOESM3_ESM.pdf (1 mb)
Online resource 3 Regulation of “Mouse embryonic stem cells pluripotency” signaling pathway in response to doxorubicin treatment of Hs578T cells. Genes highlighted in red were found to be up-regulated by doxorubicin treatment, while the genes highlighted in green were down-regulated (pdf 1064 kb)
11010_2015_2522_MOESM4_ESM.pdf (1.4 mb)
Online resource 4 Regulation of “Role of OCT4 in Mammalian Embryonic Stem Cell Pluripotency” signaling pathway in response to doxorubicin treatment of Hs578T cells. Genes highlighted in red were found to be up-regulated by doxorubicin treatment, while the genes highlighted in green were down-regulated (pdf 1448 kb)
11010_2015_2522_MOESM5_ESM.pdf (1.2 mb)
Online resource 5 Regulation of “Role of Nanog in Mammalian Embryonic Stem Cell Pluripotency” signaling pathway in response to doxorubicin treatment of Hs578T cells. Genes highlighted in red were found to be up-regulated by doxorubicin treatment, while the genes highlighted in green were down-regulated (pdf 1260 kb)

References

  1. 1.
    Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820–13825. doi: 10.1073/pnas.0905718106 PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    von Minckwitz G, Martin M (2012) Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol 23(Suppl 6):vi35-39. doi: 10.1093/annonc/mds193 Google Scholar
  3. 3.
    Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14(10):933–942. doi: 10.1016/S1470-2045(13)70335-8 CrossRefPubMedGoogle Scholar
  4. 4.
    Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C, Breast Cancer International Research Group I (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313. doi: 10.1056/NEJMoa043681 CrossRefPubMedGoogle Scholar
  5. 5.
    Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27(8):1168–1176. doi: 10.1200/JCO.2008.18.1024 PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Minami CA, Chung DU, Chang HR (2011) Management options in triple-negative breast cancer. Breast Cancer 5:175–199. doi: 10.4137/BCBCR.S6562 PubMedCentralPubMedGoogle Scholar
  7. 7.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334. doi: 10.1158/1078-0432.CCR-06-1109 CrossRefPubMedGoogle Scholar
  8. 8.
    Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233–247. doi: 10.1146/annurev-med-070909-182917 PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631–643. doi: 10.1038/nrc2713 CrossRefPubMedGoogle Scholar
  10. 10.
    Moitra K, Lou H, Dean M (2011) Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89(4):491–502. doi: 10.1038/clpt.2011.14 CrossRefPubMedGoogle Scholar
  11. 11.
    Liu S, Wicha MS (2010) Targeting breast cancer stem cells. J Clin Oncol 28(25):4006–4012. doi: 10.1200/JCO.2009.27.5388 CrossRefPubMedGoogle Scholar
  12. 12.
    Ablett MP, Singh JK, Clarke RB (2012) Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer 48(14):2104–2116. doi: 10.1016/j.ejca.2012.03.019 CrossRefPubMedGoogle Scholar
  13. 13.
    Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS (2008) Cancer stem cells in breast: current opinion and future challenges. Pathobiology 75(2):75–84. doi: 10.1159/000123845 PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimaki A, Virkkunen P, Tarkkanen M, Hakkarainen T, Kanerva A, Rein D, Pesonen S, Hemminki A (2008) Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 68(14):5533–5539. doi: 10.1158/0008-5472.CAN-07-5288 CrossRefPubMedGoogle Scholar
  15. 15.
    Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H (2005) Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11(3):1154–1159PubMedGoogle Scholar
  16. 16.
    Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M (2009) Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest 89(8):857–866. doi: 10.1038/labinvest.2009.54 CrossRefPubMedGoogle Scholar
  17. 17.
    Chavez KJ, Garimella SV, Lipkowitz S (2010) Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 32(1–2):35–48. doi: 10.3233/BD-2010-0307 PubMedCentralPubMedGoogle Scholar
  18. 18.
    Smalley M, Piggott L, Clarkson R (2013) Breast cancer stem cells: obstacles to therapy. Cancer Lett 338(1):57–62. doi: 10.1016/j.canlet.2012.04.023 CrossRefPubMedGoogle Scholar
  19. 19.
    Lovitt CJ, Shelper TB, Avery VM (2014) Advanced cell culture techniques for cancer drug discovery. Biology 3(2):345–367. doi: 10.3390/biology3020345 PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G, Clarke RB (2012) A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia 17(2):111–117. doi: 10.1007/s10911-012-9255-3 CrossRefPubMedGoogle Scholar
  21. 21.
    Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68. doi: 10.1186/bcr2635 PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1(1):84–96. doi: 10.1016/j.molonc.2007.02.004 PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Holliday DL, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13(4):215. doi: 10.1186/bcr2889 PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21(7):440–446. doi: 10.1097/FPC.0b013e32833ffb56 PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Collins I, Weber A, Levens D (2001) Transcriptional consequences of topoisomerase inhibition. Mol Cell Biol 21(24):8437–8451. doi: 10.1128/MCB.21.24.8437-8451.2001 PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Hernandez-Vargas H, Palacios J, Moreno-Bueno G (2007) Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26(20):2902–2913. doi: 10.1038/sj.onc.1210102 CrossRefPubMedGoogle Scholar
  27. 27.
    Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH (2005) Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 5:7. doi: 10.1186/1471-2407-5-7 PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Knappskog S, Chrisanthar R, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lonning PE (2012) Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 14(2):R47. doi: 10.1186/bcr3147 PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6(12):924–935. doi: 10.1038/nrc2013 CrossRefPubMedGoogle Scholar
  30. 30.
    Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672–679. doi: 10.1093/jnci/djn123 CrossRefPubMedGoogle Scholar
  31. 31.
    Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA (2010) Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76(3):889–895. doi: 10.1016/j.ijrobp.2009.09.052 PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10(2):R25. doi: 10.1186/bcr1982 PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. doi: 10.1016/j.stem.2007.08.014 PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6):1109–1123. doi: 10.1016/j.cell.2007.10.054 CrossRefPubMedGoogle Scholar
  35. 35.
    Alamgeer M, Ganju V, Kumar B, Fox J, Hart S, White M, Harris M, Stuckey J, Prodanovic Z, Schneider-Kolsky ME, Watkins DN (2014) Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res 16(2):R44. doi: 10.1186/bcr3648 PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS, Park SY (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104(11):1730–1738. doi: 10.1038/bjc.2011.159 PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI (2011) The CD44+/CD24- phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients. Med Oncol 28(3):745–752. doi: 10.1007/s12032-010-9530-3 CrossRefPubMedGoogle Scholar
  38. 38.
    Greaves M (2010) Cancer stem cells: back to Darwin? Semin Cancer Biol 20(2):65–70. doi: 10.1016/j.semcancer.2010.03.002 CrossRefPubMedGoogle Scholar
  39. 39.
    Chuthapisith S, Eremin J, El-Sheemey M, Eremin O (2010) Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 19(1):27–32. doi: 10.1016/j.suronc.2009.01.004 CrossRefPubMedGoogle Scholar
  40. 40.
    Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH (2012) CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43(3):364–373. doi: 10.1016/j.humpath.2011.05.005 CrossRefPubMedGoogle Scholar
  41. 41.
    Many AM, Brown AM (2010) Mammary stem cells and cancer: roles of Wnt signaling in plain view. Breast Cancer Res 12(5):313. doi: 10.1186/bcr2631 PubMedCentralPubMedGoogle Scholar
  42. 42.
    Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176(6):2911–2920. doi: 10.2353/ajpath.2010.091125 PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA (2012) Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/beta-catenin signaling. Stem Cells 30(11):2366–2377. doi: 10.1002/stem.1219 PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR 3rd, Nusse R (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423(6938):448–452. doi: 10.1038/nature01611 CrossRefPubMedGoogle Scholar
  45. 45.
    Qu F, Wang J, Xu N, Liu C, Li S, Wang N, Qi W, Li H, Li C, Geng Z, Liu Y (2013) WNT3A modulates chondrogenesis via canonical and non-canonical Wnt pathways in MSCs. Front Biosci 18:493–503CrossRefGoogle Scholar
  46. 46.
    Wong RC, Tellis I, Jamshidi P, Pera M, Pebay A (2007) Anti-apoptotic effect of sphingosine-1-phosphate and platelet-derived growth factor in human embryonic stem cells. Stem Cells Dev 16(6):989–1001. doi: 10.1089/scd.2007.0057 CrossRefPubMedGoogle Scholar
  47. 47.
    Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS, Arteaga CL (2013) TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 123(3):1348–1358. doi: 10.1172/JCI65416 PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Ferrigno O, Lallemand F, Verrecchia F, L’Hoste S, Camonis J, Atfi A, Mauviel A (2002) Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene 21(32):4879–4884. doi: 10.1038/sj.onc.1205623 CrossRefPubMedGoogle Scholar
  49. 49.
    Ampuja M, Jokimaki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo EL, Kallioniemi A (2013) BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC Cancer 13:429. doi: 10.1186/1471-2407-13-429 PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Ono Y, Calhabeu F, Morgan JE, Katagiri T, Amthor H, Zammit PS (2011) BMP signalling permits population expansion by preventing premature myogenic differentiation in muscle satellite cells. Cell Death Differ 18(2):222–234. doi: 10.1038/cdd.2010.95 PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Arakaki M, Ishikawa M, Nakamura T, Iwamoto T, Yamada A, Fukumoto E, Saito M, Otsu K, Harada H, Yamada Y, Fukumoto S (2012) Role of epithelial-stem cell interactions during dental cell differentiation. J Biol Chem 287(13):10590–10601. doi: 10.1074/jbc.M111.285874 PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Guo D, Huang J, Gong J (2012) Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer. Mol Cell Biochem 363(1–2):179–190. doi: 10.1007/s11010-011-1170-1 CrossRefPubMedGoogle Scholar
  53. 53.
    Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, Woltjen K, Nagy A, Wrana JL (2010) Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 7(1):64–77. doi: 10.1016/j.stem.2010.04.015 CrossRefPubMedGoogle Scholar
  54. 54.
    Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R, Stassi G (2011) Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140(1):297–309. doi: 10.1053/j.gastro.2010.10.005 CrossRefPubMedGoogle Scholar
  55. 55.
    Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, Gao J, Wang H, Zhang Y (2013) Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem Cells 31(3):433–446. doi: 10.1002/stem.1298 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Oana Tudoran
    • 1
    • 2
    Email author
  • Olga Soritau
    • 1
  • Loredana Balacescu
    • 1
    • 2
  • Simona Visan
    • 1
    • 3
  • Otilia Barbos
    • 1
  • Roxana Cojocneanu-Petric
    • 2
  • Ovidiu Balacescu
    • 1
  • Ioana Berindan-Neagoe
    • 1
    • 2
  1. 1.Department of Functional Genomics and Experimental PathologyThe Oncology Institute I. Chiricuta, Cluj-NapocaCluj-NapocaRomania
  2. 2.Research Center for Functional Genomics, Biomedicine and Translational MedicineIuliu Hatieganu University of Medicine and PharmacyCluj-NapocaRomania
  3. 3.Department of Pathologic Anatomy, Necropsy and Veterinary Forensic MedicineUniversity of Agricultural Sciences and Veterinary MedicineCluj-NapocaRomania

Personalised recommendations